Exelixis, Inc. (EXEL) stock
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/303% above fair value
$68.29−0.21 (-0.31%)
Close on Nov 18, 2026Market cap $16.66BP/E 20.4Yield –
Exelixis market cap
Market capitalization is the share price multiplied by the number of shares outstanding.
Exelixis's market cap was $17.60B on Nov 11, 2026, against $11.84B a year earlier. Over the last 5 years it ranged from $5.05B to $17.60B, with a median of $7.23B.
Market Cap at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $17.60B | +49.7% |
| 2025 | Dec 31, 2025 | $11.75B | +23.5% |
| 2024 | Dec 31, 2024 | $9.52B | +27.6% |
| 2023 | Dec 29, 2023 | $7.46B | +44.2% |
| 2022 | Dec 30, 2022 | $5.17B | -10.5% |
| 2021 | Dec 31, 2021 | $5.78B | -6.9% |
| 2020 | Dec 31, 2020 | $6.21B | +16.0% |
| 2019 | Dec 31, 2019 | $5.35B | -9.0% |
| 2018 | Dec 31, 2018 | $5.88B | -34.6% |
| 2017 | Dec 29, 2017 | $8.99B | +110.7% |
| 2016 | Dec 30, 2016 | $4.27B | +234.5% |
| 2015 | Dec 31, 2015 | $1.28B | +353.8% |
| 2014 | Dec 31, 2014 | $281.06M | -75.1% |
| 2013 | Dec 31, 2013 | $1.13B | +34.7% |
| 2012 | Dec 31, 2012 | $838.54M | -0.4% |
| 2011 | Jul 29, 2011 | $841.51M | -4.3% |
| 2010 | Dec 31, 2010 | $879.07M | – |
See a number that looks wrong?